---
schema_version: "secwatch.filing_event.v1"
accession: "0001619856-25-000070"
form_type: "8-K"
ticker: "CRBU"
cik: "0001619856"
company_name: "Caribou Biosciences, Inc."
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T21:13:14.039066+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Caribou Biosciences reports Q3 2025 clinical data: vispa-cel 86% ORR, CB-011 92% ORR; cash $159.2M

## Summary
- Vispa-cel ANTLER phase 1: 86% ORR, 63% CR, 53% PFS at 12mo in 35 patients with optimized profile (≥2 HLA match, young donor).
- CB-011 CaMMouflage phase 1: 92% ORR, 75% ≥CR, 91% MRD-negativity in 12 BCMA-naïve patients at recommended dose.
- Cash, equivalents, and marketable securities $159.2M as of Sep 30, 2025; expected to fund operations into 2H 2027.
- Q3 2025 revenue $2.2M (vs $2.0M Q3 2024); R&D expenses $22.4M (down from $30.4M); G&A $9.2M (down from $9.8M).
- FDA recommends randomized controlled trial for vispa-cel pivotal phase 3 in 2L LBCL; company to refine design with FDA.

## SEC filing metadata
- accession: 0001619856-25-000070
- form_type: 8-K
- ticker: CRBU
- cik: 0001619856
- company_name: Caribou Biosciences, Inc.
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1619856/000161985625000070/0001619856-25-000070-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1619856/000161985625000070/crbu-20251112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001619856-25-000070
- JSON: https://secwatch.observer/filing/0001619856-25-000070.json
- Plain text: https://secwatch.observer/filing/0001619856-25-000070.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.